阿扎胞苷联合CAG方案再诱导治疗儿童复发难治急性髓系白血病临床观察  

Clinical observation of azacitidine combined with CAG regimen in reinduction treatment of pediatric relapsed/refractory acute myeloid leukemia

作　　者：郑湧智 郑浩[1] 胡建达[1] Zheng Yongzhi;Zheng Hao;Hu Jianda(Department of Pediatric Hematology,Fujian Medical University Union Hospital,Fujian Institute of Hematology,Fujian Provincial Key Laboratory on Hematology,Fuzhou 350001,China)

机构地区：[1]福建医科大学附属协和医院小儿血液科,福建省血液病研究所福建省血液病学重点实验室,福州350001

出　　处：《白血病．淋巴瘤》2021年第8期470-474,共5页Journal of Leukemia & Lymphoma

基　　金：福建省血液医学中心建设项目(闽政办(2017)4号)。

摘　　要：目的探讨阿扎胞苷联合CAG(阿糖胞苷+阿柔比星+粒细胞集落刺激因子)方案再诱导儿童复发难治急性髓系白血病(AML)的疗效和安全性。方法回顾性分析2018年11月至2019年8月福建医科大学附属协和医院收治的3例接受阿扎胞苷联合CAG方案再诱导治疗的复发难治AML患儿的临床资料,分析疗效、预后及不良反应发生情况。结果3例患儿中,2例为复发AML(分别距开始治疗18个月和8个月后复发),1例为难治AML(2个疗程标准化疗不能达完全缓解)。在2个疗程阿扎胞苷联合CAG方案再诱导后,2例达完全缓解,1例达部分缓解,之后均桥接造血干细胞移植(HSCT)。随访16~21个月(距首次阿扎胞苷联合CAG方案再诱导的时间),患儿均为无白血病生存。除了血液学不良反应及感染外,阿扎胞苷未增加其他不良反应。结论阿扎胞苷联合CAG方案诱导儿童复发难治AML有较高的再缓解率和安全性,及时桥接HSCT可取得较好的预后。Objective To investigate the efficacy and safety of azacitidine combined with CAG(cytarabine+aclacinomycin+granulocyte colony-stimulating factor)regimen in reinduction treatment of pediatric relapsed/refractory acute myeloid leukemia(AML)patients.Methods The clinical data of 3 pediatric patients with relapsed/refractory AML treated with azacitidine combined with CAG regimen reinduction in Fujian Medical University Union Hospital between November 2018 and October 2019 were retrospectively analyzed,and the efficacy,prognosis and adverse reactions were also analyzed.Results Among 3 patients,2 cases were relapsed AML(relapse time began 18 months and 8 months after treatment started,respectively),and 1 case was refractory AML(cannot achieve complete remission after 2 courses of standard chemotherapy).After 2 courses of azacitidine combined with CAG regimen reinduction,2 cases achieved complete remission,and 1 case achieved partial remission.And then they all underwent hematopoietic stem cell transplantation(HSCT)and had leukemia-free survival after 16-21 months follow-up(time from the first azacitidine combined with CAG reinduction).Except for hematological adverse reactions and infection,azacitidine did not increase other adverse effects.Conclusions Azacitidine combined with CAG regimen in reinduction treatment of pediatric relapsed/refractory AML has a higher remission rate and safety,and patients undergoing timely bridging HSCT may have a good prognosis.

关 键 词：白血病 髓样 急性 儿童 抗肿瘤联合化疗方案 阿扎胞苷 

分 类 号：R733.71[医药卫生—肿瘤]